Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04253561 | Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients(IPATHER) | completed | Phase 1 | 17 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06332508 | Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL) | completed | Phase 1 | 14 | National University Hospital, SingaporeOTHER | 1 | Mar 13, 2026 |
| clinicaltrials |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT01597388 | AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer | completed | Phase 1 | 99 | AstraZenecaINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02063724 | HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer(Adjuvant) | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT02776436 | Reducing Dexamethasone Around Docetaxel Infusion(REDEX) | completed | Phase 1 | 46 | Leiden University Medical CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02499146 | Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer | completed | Phase 1 | 26 | PfizerINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT02520063 | Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 15 | University of Alabama at BirminghamOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT02999477 | A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer | completed | Phase 1 | 32 | Adrienne G. WaksOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04481113 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | completed | Phase 1 | 8 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04640480 | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | completed | Phase 1 | 21 | SN BioScienceINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04991480 | A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | completed | Phase 1 | 93 | Artios Pharma LtdINDUSTRY | 2 | Jan 27, 2026 | clinicaltrials |
| NCT07229560 | A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants | completed | Phase 1 | 16 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03685331 | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | completed | Phase 1 | 9 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06846099 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 | completed | Phase 1 | 69 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03310957 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 1 / Phase 2 | 185 | Seagen Inc.INDUSTRY | 4 | Dec 12, 2025 | clinicaltrials |
| NCT03542175 | A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | completed | Phase 1 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03807765 | Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02950259 | Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) | completed | Phase 1 | 16 | Providence Health & ServicesOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02639026 | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | completed | Phase 1 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01373710 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis(HIT) | completed | Phase 1 / Phase 2 | 34 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03109080 | Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)(RadioPARP) | completed | Phase 1 | 24 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04647487 | A Study of LY3484356 in Women With Breast Cancer Before Having Surgery(EMBER-2) | completed | Phase 1 | 87 | Eli Lilly and CompanyINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT03280563 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer(MORPHEUS HR+BC) | completed | Phase 1 / Phase 2 | 144 | Hoffmann-La RocheINDUSTRY | 3 | Nov 10, 2025 | clinicaltrials |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | completed | Phase 1 | 182 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Nov 5, 2025 | clinicaltrials |
| NCT04568902 | Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | completed | Phase 1 | 33 | Eisai Co., Ltd.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05082610 | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Hummingbird BioscienceINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04023110 | Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab(CCTGuide Pilot) | completed | Phase 1 | 68 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT05501769 | ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer(TACTIVE-E) | completed | Phase 1 | 32 | Arvinas Estrogen Receptor, Inc.INDUSTRY | 2 | Sep 26, 2025 | clinicaltrials |
| NCT04664829 | The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC | completed | Phase 1 | 12 | National Cancer Centre, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03944499 | Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. | completed | Phase 1 | 161 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04892342 | Study of ESG401 in Adults With Solid Tumors | completed | Phase 1 / Phase 2 | 156 | Shanghai Escugen Biotechnology Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | completed | Phase 1 | 34 | TakedaINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04487236 | Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors | completed | Phase 1 | 61 | Suzhou Zanrong Pharma LimitedINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02776917 | Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer | completed | Phase 1 | 23 | Barbara Parker, MDOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04541433 | A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer | completed | Phase 1 | 10 | AstraZenecaINDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03348293 | Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction | completed | Phase 1 | 30 | Xijing HospitalOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06048367 | Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor(CNSI-Fe(II)) | completed | Phase 1 | 19 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03654547 | Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | completed | Phase 1 | 48 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 2 | Jul 24, 2025 | clinicaltrials |
| NCT06886659 | A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche) | completed | Phase 1 | 80 | Incepta Pharmaceuticals LtdINDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT03199586 | Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies | completed | Phase 1 | 23 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT03106415 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03767335 | MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer(B-PRECISE-01) | completed | Phase 1 | 62 | Menarini GroupINDUSTRY | 6 | Jun 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 16, 2026source: clinicaltrials